Zydus Lifesciences has informed that it enclosed two press releases, both dated February 20, 2023 titled ‘Zydus receives tentative approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 mg and 600 mg’ and ‘Zydus receives tentative approval from the USFDA for Canagliflozin and Metformin Hydrochloride Tablets’.
The above information is a part of company’s filings submitted to BSE.